Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b/2 Open-Label Study of APVO436 in Combination With Venetoclax and Azacitidine in Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)

NCT06634394 is registered in ClinicalTrials.gov with Aptevo Therapeutics as lead sponsor.

NCT NCT06634394
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06634394 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b/2 Open-Label Study of APVO436 in Combination With Venetoclax and Azacitidine in Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)
Lead sponsor
Aptevo Therapeutics
Phase
Phase 1
Overall status
Recruiting
Start date
October 1, 2024
Completion date
March 31, 2028
Enrollment
39 (estimated)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leukemia (aml)